Patients
From January 13, 2016, to August 27, 2021, a total of 161 patients (87 [54.0%] women, 74 [46.0%] men; mean [SD] age, 55 [9.8] years; range, 26-80 years) were enrolled and randomized to receive gefitinib (n = 81) or gefitinib plus chemotherapy (n = 80) (eFigure 1 in 